Integer Stock Down 28% as Insider Reports Sale. Here's What to Know

Tom Thomas, VP Corporate Controller, sold 825 shares of Integer (ITGR) in an open-market transaction on March 13, 2026 for $70,000, representing 15.85% of his direct holdings and leaving him with 4,381 direct shares valued at ~$364K. Integer reported roughly $1.85B in 2025 sales (up 8% YoY), adjusted operating income +13% and adjusted EPS +21%, but shares are down ~27.7% over the past year and leverage is elevated near 3.0x EBITDA with debt rising $195M to $1.185B. The insider sale is characterized as routine liquidity management and is unlikely to materially affect the stock; the larger investor focus remains on converting revenue growth into sustained margin expansion and balance sheet improvement.

Analysis

Integer sits at the crossroads of two secular forces: OEMs pushing more complexity into outsourced partners and capital-intensive capacity/margin compression at the contract-manufacturing layer. That dynamic gives Integer pricing and share-gain potential on new, higher-margin product ramps (neuromodulation, bespoke battery systems) but requires near-term investment and execution discipline — a classic capital allocation inflection where small execution slippage materially impacts free cash flow and multiple.

Near-term catalysts to watch are sequential margin trajectory and cash-flow conversion over the next 2-4 quarters; these will signal whether recent top-line momentum is starting to flow through to operating leverage or simply funding working capital and integration costs. Tail risks that would reverse a constructive view are concentrated — a meaningful OEM program delay, a regulatory/manufacturing quality event, or refinancing stress if markets remain rate-sensitive — each would steepen the downside path much faster than a typical demand slowdown.

The market’s current stance appears to underweight the stickiness of long-term OEM relationships and the embedded option value of differentiated battery + implantable-device franchises; if management prioritizes deleveraging and free cash flow over acquisitive growth, Integer can reprice quickly. Conversely, if capital is redeployed into low-return tuck-ins, downside will be amplified; monitor guidance cadence, cost-out realization, and debt-repayment schedule as 3 concrete triggers that should move the stock materially within 6–18 months.

Key Decisions for Investors

• Directional long (tactical, asymmetric): Buy ITGR Jan-2027 call spread — purchase a ~30-delta call and sell a higher strike ~10-delta call to finance premium. Time horizon 12–18 months. Rationale: low-cost exposure to margin/deleveraging play; max loss = premium; upside if 200–300bps margin improvement and single-turn multiple expansion occurs.
• Income / staged accumulation: Acquire a small core long position in ITGR and sell 6–9 month OTM covered calls to fund basis. Size as 2–3% of deployable capital; roll if calls are assigned or if visible margin improvement continues. Risk: capping upside; benefit: yield while waiting for execution clarity.
• Tail-hedged long: For larger exposure, pair long ITGR equity with purchase of 9–12 month puts equal to ~20% notional (protect downside from operational/regulatory shocks). Time horizon 12 months; cost justified if exposure is >5% of book because it caps catastrophic idiosyncratic risk while retaining upside.
• Event/relative value pair: Long ITGR / short a diversified medtech OEM (e.g., MDT or ABT) — horizon 6–12 months to isolate manufacturing share gains versus OEM cyclicality. Use modest sizing and equal-dollar legs to neutralize market beta; unwind if OEM end-market indicators deteriorate broadly.